Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis

Brenda C. Edina 1, Jeremy R. Tandaju 1, Lowilius Wiyono 1

1. Faculty of Medicine, Universitas Indonesia, Jakarta, IDN

Abstract

Type 2 diabetes mellitus is a prevalent metabolic disease requiring tight glycemic control of basal and postprandial glucose levels. Treatment intensification using separate basal and bolus injections increased the number of injections and reduced cost-effectiveness, leading to decreased compliance and failure of glycemic control. Insulin Degludec/Insulin Aspart (IDegAsp), a novel premix of basal and bolus insulin, is one of the potential treatments for reducing the number of injections. However, its efficacy and safety have not been reviewed clearly. Therefore, this systematic review aims to compare the efficacy and safety of IDegAsp with standard basal and basal plus bolus insulin regimens.

A systematic review of four databases (Pubmed, Scopus, Science Direct, and Proquest) was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Search results were screened by eligibility criteria and critically appraised by the Oxford Centre for Evidence-Based Medicine (CEBM) tool and the Cochrane risk-of-bias assessment tool. Meta-Analysis was done using Review Manager to obtain cumulative outcomes from hemoglobin A1C (HbA1C) changes, hypoglycemia incidents, and weight gain from all studies.

Out of 132 search results, 10 studies were reviewed. IDegAsp once-daily administration was proven beneficial in reducing HbA1c levels and nocturnal hypoglycemia incidences, while IDegAsp twice-daily administration was proven beneficial in lowering hypoglycemia incidence and nocturnal hypoglycemia incidence. IDegAsp yielded better glycemic index results and lowered hypoglycemic incidents in the meta-analysis.

Thus, it is concluded that IDegAsp once daily with stepwise titration on the largest meal of the day achieved most benefits with minimal risks.

Introduction And Background

Diabetes mellitus is a metabolic disease suffered by 422 million people globally (2014) and a direct cause of 1.6 million mortalities (2016) due to its complications [1]. Type 2 diabetes mellitus (T2DM), a subtype of diabetes mellitus more prevalent in adults, is characterized by impaired glucose metabolism, insulin resistance, and progressive insulin deficiency. Changes in glucose homeostasis in T2DM create a continuous state of hyperglycemia in blood plasma. If glycemia is not controlled through the course of the disease, chronic hyperglycemia may lead to various long-term complications (macrovascular and microvascular), which lead to poor quality of life, increased morbidity, and mortality [2,3].

Based on the clinical guidelines from the American Diabetes Association and European Association for the Study of Diabetes, glycemic control of T2DM is done by combining lifestyle changes and pharmacological intervention through a stepwise approach. The first line of pharmacological treatment for T2DM is oral hyperglycemic agents. However, in cases of progressive beta-cell destruction and insulin deficiency where glycemic control could not be adequately achieved by only using oral anti-glycemic agents, treatment is intensified by adding basal insulin therapy or glucagon-like peptide-1 (GLP-1) receptor agonist. One of the challenges of basal insulin therapy is the control of postprandial glucose levels. When postprandial glucose levels still spike even after constant basal insulin therapy, post-prandial or bolus insulin injection may be added to treatment regimens [2,3].

The use of basal and postprandial insulin may be effective in controlling blood glucose levels; however, it requires more daily injections and increases the cost of treatment, risk of hypoglycemia, and risk of error in usage by patients. These drawbacks may be inconvenient for most patients, as injections are uncomfortable for most. Aside from the inconveniences, an increased number of injections leads to reduced treatment compliance, thus hampering the effectiveness of glycemic control. Patients may come to the hospital even
more morbidly than before their treatment was intensified, only because they missed most of their insulin injections [2,3].

As a solution to this, several pre-mixed or self-mixed insulin solutions were innovated. Although most of the time coformulation of basal and bolus insulin is impossible due to substance incompatibility, some long-acting and rapid-acting insulin combinations have been formulated. One of them is insulin degludec/insulin aspart (IDegAsp), a soluble co-formulation consisting of 70% basal insulin degludec and 30% postprandial insulin aspart [2,3].

IDegAsp is a potential T2DM treatment due to its glycemic coverage and reduced number of injections. However, to date, there has not been any comparison of IDegAsp with standard treatments (basal insulin or basal and bolus insulin) stratified by its frequency. A review of IDegAsp’s efficacy is needed to give a clear risk and benefit consideration for clinical practitioners in prescribing insulin therapies. Therefore, we created a systematic review comparing the efficacy and safety of IDegAsp to that of basal insulin regimen and basal plus bolus insulin regimen, stratified by its frequency, once daily or twice daily.

**Review**

**Materials and methods**

We conducted a systematic review complying with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to determine the efficacy and safety of IDegAsp in the management of T2DM [4]. The literature search and screening method were then summarized in the PRISMA statement flowchart in Figure 1.

**Search Strategy**

The search strategy was conducted independently by three reviewers (BCE, LW, and JRT) to ensure the reviewers’ objectivity. The search was conducted through PubMed, ProQuest, Scopus, and ScienceDirect on October 29, 2020. Each difference in search results was discussed further between the reviewers to make a decision. We also conducted hand searching with citation searching from the previously included studies to look for literature on IDegAsp and Type 2 DM. The search was conducted using search queries and keywords of (“Type 2 Diabetes Mellitus” OR “Type 2 DM”) AND “IDegAsp” in every database. A Medical Subject Headings (MeSH) term was used if it is available in the selected databases. Moreover, we contacted experts and researchers from the field to look for potential unscreened data and searched clinical trials on clinicaltrial.gov to look for the latest publication on IDegAsp and T2DM.

**Study Selection**

We selected and screened the studies using inclusion and exclusion criteria that preceded the research. All screening processes were done using Google Spreadsheet (Google LLC, Mountain View, California, United
States). The study selection was done based on the predetermined patient, intervention, control, and outcome (PICO) criteria, in which we used T2DM as the targeted patient, IDegAsp as intervention, other insulin therapy as the control (insulin glargine, insulin aspart, etc.), and primary outcomes of insulin use, that is the changes in hemoglobin A1C (HbA1C) value (for efficacy) and hypoglycemia incident rate (for safety). We included studies with several inclusion criteria, including (1) randomized clinical trials, (2) studying a population of T2DM at any age, (3) using IDegAsp as an intervention or independent variable, (4) using another insulin as a controlled variable, (5) analyzing the outcome of IDegAsp use in T2DM, such as HbA1C changes and hypoglycemia events that compared with the control insulin, and (6) written in English. We also did citation alerts from existing systematic reviews or meta-analyses to increase the sensitivity of the acquired studies. However, we excluded editorial/review articles and case reports/case series as they were not suitable for this review. Articles on animal studies (non-human studies), inaccessible full-text articles, and non-English articles were also excluded. The selection process was conducted by adhering to PRISMA guidelines, starting from the title and abstract screening, followed by full-text screening. All screening processes were done independently by all investigators (BCE, LW, JRT). Every discrepancy or uncertainty was discussed by all investigators.

Quality Assessment

All acquired studies were then assessed for their quality using tools for critical appraisal by the Centre for Evidence-Based Medicine (CEBM) of the University of Oxford [5]. The critical appraisals were done in three different sections: validity, importance, and applicability. We also conducted a risk-of-bias assessment using Cochrane’s tool for risk-of-bias on seven different aspects of bias, which included selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), attrition bias (incomplete outcome data), detection bias (blinding of outcome assessment), and reporting bias (selective reporting) [6]. The critical appraisal and risk-of-bias assessment were conducted by three independent reviewers, with any disparities and differences discussed properly to make a final decision, and extrapolated into tables.

Data Extraction

Out of the selected studies, we extracted the information of study author, year, design, location, age of samples, sample size, intervention, control, the aim of the study, the primary endpoint, level of evidence (based on CEBM level of evidence 2011 [7]), and the length of each included study (the time period of data retrieval). The selected outcomes recorded in the review comprised HbA1C changes, proportions of participants achieving normal HbA1C (7%), hypoglycemia incident rate, nocturnal hypoglycemia incident rate, weight gain, and fasting glucose changes. The data were then extrapolated into tables and forest plots.

Meta-Analysis

All included studies were then included for quantitative analysis. The meta-analysis was done using Review Manager (RevMan) Version 5.4 (2020; The Cochrane Collaboration, London, England). All recorded outcomes were used in the pooled analysis, consisting of HbA1C changes, weight gain, and fasting glucose changes, which were reported in estimated treatment differences (ETD) value; proportions of participants achieving normal HbA1C, which were reported in odds ratio (OR); hypoglycemia incident rate and nocturnal hypoglycemia incident rate, which were reported in risk ratio (RR). Summary data and related 95% confidence interval (CI) were then calculated by conventional meta-analysis. Quantitative analysis for HbA1C changes, weight gain, and fasting glucose was conducted using fixed-effect inverse variance with continuous type of data with effect measure of mean difference. Analysis of proportions of participants achieving HbA1C changes was done using the fixed-effect Mantel-Haenszel method with dichotomous type of data with effect measure of OR. Meanwhile, analysis of hypoglycemia and nocturnal hypoglycemia incident rate was conducted using fixed-effect inverse variance with generic inverse variance type of data with effect measures of RR. All the analyses were conducted by dividing the included studies into four different subgroups, comprising "IDegAsp vs Once-daily Insulin Glargine (IGlar OD)" group, "IDegAsp vs Once-daily Insulin Glargine and Insulin Aspart (IGlar+IAsp OD)" group, "IDegAsp vs Bi-daily Insulin Aspart (BIAsp BD)" group, and "IDegAsp vs Bi-daily Insulin Degludec and Insulin Aspart (IDeg+IAsp BD)" group based on the frequency and control regimen of each study. All results were then visualized into forest plots and funnel plots. The indexes of heterogeneity (X2 or Q according to Cochran, I², and tau²) were also calculated to analyze data distribution in each study. All analyses were made using the predetermined p-value of below 0.05 to be considered as significant.

Results

Study Selection and Study Characteristics

According to the search strategy, we found 10 studies eligible for analysis out of 132 articles initially meeting the search criteria from various databases (Figure 1). There are three studies comparing once-daily administration of IDegAsp to once-daily administration of insulin glargine (IGlar) [3,8,9], one study comparing once-daily administration of IDegAsp to once-daily administration of combined insulin glargine
and insulin aspart (IAsp) [2], five studies comparing twice a day administration of IDegAsp to twice a day administration of biphasic insulin aspart (BIAsp) [10-14], and one study comparing twice a day administration of IDegAsp to twice a day administration of IDeg and IAsp [15]. All studies were randomized controlled studies, with some done in phase III [9,11-13,15]. There were seven multinational and intercontinental studies [2,3,8,10-12,15]. All studies involved patients aged 18 years old and above with a sample size of more than 100 for each study. Table 1 gives the details of the selected studies with complete characteristics.

| Author           | Year | Design | Location                                      | Age (years) | Sample size | Objective                                                                 | Primary Endpoint | Level of Evidence | Length (weeks) |
|------------------|------|--------|-----------------------------------------------|-------------|-------------|---------------------------------------------------------------------------|------------------|------------------|----------------|----------------|
| Kumar et al. [3] | 2016 | RCT    | Croatia, France, India, Poland, South Africa, South Korea, Sweden, Turkey, United States | >18         | 465         | HbA1c mean change, FPG change, SMPG 9 point, overall prandial glucose increment | HbA1c mean change | 1b               | 26             |
| Kumar et al [8]  | 2016 | RCT    | Austria, India, Poland, Russia, South Korea, Spain, Turkey, United States | >18         | 413         | HbA1c change, FPG change, PPG increment SMPG, number of participants with normal HbA1c, hypoglycemic episodes | HbA1c change     | 1b               | 26 + 26        |
| Onishi et al. [9] | 2013 | RCT    | Japan                                         | >20         | 296         | HbA1c change, FPG change, SMPG nine-point, total daily insulin dose, hypoglycemic episodes, body weight | HbA1c change     | 1b               | 26             |
| Tsimikas et al. [2] | 2019 | RCT    | Algeria, Czech, India, Russia, Serbia, Turkey, US | >18         | 532         | HbA1c mean change, FPG change, proportion of normal HbA1c, SMPG profile, total daily insulin dose | HbA1c change     | 1b               | 26             |
| Kaneko et al. [10]| 2015 | RCT    | Hong Kong, Japan, Malaysia, South Korea, Taiwan | >18         | 424         | HbA1c change, FPG change, 9 point SMPG, body weight, proportion achieving normal HbA1c | HbA1c change     | 1b               | 26             |
| Fulcher et al. [11] | 2014 | RCT Phase III | Australia, Denmark, Finland, India, Malaysia, Poland, Sweden, Taiwan, Thailand, Turkey | >18         | 447         | HbA1c change, FPG change, SMPG profile, proportion achieving normal hba1c, hypoglycemic episodes, body weight, insulin dose | HbA1c change     | 1b               | 26             |
| Taneda et al. [12] | 2016 | RCT Phase III | Hong Kong, Japan, Malaysia, South Korea, Taiwan | -           | 178         | HbA1c change, FPG change, SMPG profile, proportion achieving normal hba1c, hypoglycemic episodes, body weight, insulin dose | HbA1c change     | 1b               | 26             |
| Yang et al. [13]  | 2019 | RCT Phase III | China                                         | >18         | 543         | HbA1c change, FPG change after 26 w, nocturnal hypoglycemia, body weight change, response without hypoglycaemic episodes | HbA1c change     | 1b               | 26             |
| Franek et al. [14] | 2016 | RCT    | Europe                                        | >18         | 371         | Safety & efficacy of IDegAsp Mean HbA1C, Events rate of hypoglycemia (nocturnal & general); ETD; Fasting glucose plasma | HbA1c change     | 1b               | 26             |
The primary outcome of the included studies includes HbA1C mean changes, fasting plasma glucose (FPG) changes, proportions of participants achieving normal HbA1C, nine-point self-measured plasma glucose (SMPG), hypoglycemic episodes, daily insulin dose, and body weight increment. Most studies were conducted for a span of 26 weeks, except for the study by Kumar et al., which was for 52 weeks [8]. However, the outcome extracted from the study still includes the 26-weeks result of the study to ensure similar characteristics for all samples.

Quality Assessment

We found out that eight studies were excellent in terms of validity and applicability according to critical appraisal (Table 2), except for one study [12], which did not state equal treatment of samples in the trial, and thus concluded as unclear.
| Study                        | Validity                  | Importance | Applicability |
|-----------------------------|---------------------------|------------|---------------|
|                            | Randomized assignment of patient | Similar characteristics of samples | Equal treatment of samples | Minimal loss-to-follow up and intention-to-treat analysis | Double-blind analysis | Treatment effect & precision | Internal validity (PICO) | Patient similarity |
| Kumar et al. [3]            | Yes                       | Yes        | Yes           | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |
| Kumar et al. [8]            | Yes                       | Yes        | Yes           | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |
| Onishi et al. [9]           | Yes                       | Yes        | Yes           | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |
| Tsikimas et al. [2]         | Yes                       | Yes        | Yes           | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |
| Yang et al. [13]            | Yes                       | Yes        | Yes           | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |
| Franek et al. [14]          | Yes                       | Yes        | Yes           | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |
| Rodbard et al. [15]         | Yes                       | Yes        | Yes           | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |
| Kaneko et al. [10]          | Yes                       | Yes        | Yes           | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |
| Fulcher et al. [11]         | Yes                       | Yes        | Yes           | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |
| Taneda et al. [12]          | Yes                       | Yes        | Unclear       | Yes                                         | Unclear               | NI                       | Yes                       | Yes                     |

**TABLE 2: Critical appraisal results**

NI: no information available on the included study

Based on the Cochrane risk-of-bias assessment, all studies were clear of selection bias, attrition bias, reporting bias, and other biases (Table 2). However, blinding of all studies was unclear because these studies have objective measures, thus blinding was not necessary.
**TABLE 3: Risk-of-bias assessment results**

| Study               | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|---------------------|---------------------------------------------|-----------------------------------------|----------------------------------------------------------|-----------------------------------------------|-----------------------------------------|-------------------------------------|------------|
| Kumar et al. [3]    | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |
| Kumar et al. [8]    | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |
| Onishi et al. [9]   | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |
| Tsimikas et al. [2] | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |
| Yang et al. [13]    | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |
| Franek et al. [14]  | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |
| Rodbard et al. [15] | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |
| Kaneko et al. [10]  | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |
| Fulcher et al. [11] | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |
| Taneda et al. [12]  | L                                           | L                                       | U                                                        | U                                             | L                                       | L                                   | L          |

**Efficacy of IDegAsp: Glycemic Index**

We found that IDegAsp administration once a day gave better HbA1c change with an estimated treatment difference (ETD) of -0.28% (95% CI -0.46; -0.10) as compared to IGlar, according to one study as seen in Table 4 [9].
### TABLE 4: Outcome of included studies

| Author | HbA1c Change | Proportion of participants achieving normal HbA1c (<7%) | Hypoglycemia incident | Nocturnal hypoglycemia incident | Weight Gain | Fasting Glucose | Other |
|--------|--------------|----------------------------------------------------------|------------------------|---------------------------------|-------------|----------------|-------|
| Kumar et al. [3] | ETD -0.03% (95% CI -0.20; 0.14) | OR 1.18 (95% CI 0.78; 1.78) | RR 1.43 (95% CI 1.07; 1.92) | RR 0.80 (95% CI 0.49; 1.30) | ETD 0.33 kg (95% CI -0.17; 0.83) | ETD 0.33 mmol/l (95% CI -0.11; 0.77) |       |
| Kumar et al. (week 26, 52) [8] | ETD -0.08% (95% CI -0.26; 0.09) | OR 0.95 (95% CI 0.66; 1.35) | TR 1.96 (95% CI 1.42; 2.44) | TR 0.25 (95% CI 0.15; 0.407) | ETD 1.60 kg (95% CI 0.84; 2.36) | ETD 0.28 mmol/l (95% CI -0.14; 0.69) |       |
| Onishi et al. [9] | ETD -0.28% (95% CI -0.46; -0.10) | OR 2.21 (95% CI 1.25; 3.92) | RR 0.73 (95% CI 0.50; 1.08) | RR 0.75 (95% CI 0.34; 1.64) | N/A | ETD -0.15 mmol/l (95% CI -0.29; 0.60) |       |
| Tsimikas et al. (week 26 and 38) [2] | ETD 0.07% (95% CI -0.06; 0.21) | OR 1.07 (95% CI 1.54) | RR 0.90 (95% CI 0.67; 1.22) | RR 0.55 (95% CI 0.34; 0.90) | ETD 0.43 kg (95% CI 0.13; 0.99) | ETD 0.04 (-0.34; 0.42) |       |
| Kaneko et al. [10] | ETD 0.05% (95% CI -0.10; 0.20) | OR 0.94 (95% CI 1.44) | RR 1.00 (95% CI 0.76; 1.32) | RR 0.67 (95% CI 0.43; 1.06) | ETD -0.38 kg (95% CI -0.96; 0.21) | ETD -1.06 mmol/l (95% CI -1.43; 0.70) |       |
| Fulcher et al. [11] | ETD -0.03% (95% CI -0.18; 0.13) | N/A | RR 0.68 (95% CI 0.52; 0.89) | RR 0.27 (95% CI 0.19; 0.41) | ETD -0.62 kg (95% CI -1.15; 0.10) | ETD -1.14 mmol/l (95% CI -1.53; 0.76) | Lower insulin dose (RR = 0.89; 95% CI 0.83; 0.96) |
| Taneda et al. [12] | ETD -0.13% (95% CI -0.31; 0.04) | OR 1.20 (95% CI 2.46) | RR 1.63 (95% CI 0.68; 4.06) | RR 0.44 (95% CI 0.20; 0.99) | ETD -0.14 kg (95% CI -1.01; 0.74) | ETD -1.50 mmol/l (95% CI -1.98; 1.01) | Lower insulin dose of 20% |
| Yang et al. [13] | ETD -0.08% (95% CI -0.20; 0.05) | OR 2.22 (95% CI 1.47; 3.35) | RR 0.57 (95% CI 0.42; 0.77) | RR 0.53 (95% CI 0.33; 0.87) | ETD 0.61 kg (95% CI 0.15; 1.08) | ETD -1.42 mmol/l (95% CI -1.74; -1.10) |       |
| Franek et al. [14] | ETD 0.02% (95% CI -0.12; 0.17) | N/A | RR 0.46 (95% CI 0.35; 0.61) | RR 0.25 (95% CI 0.16; 0.38) | ETD 0.79 kg (95% CI -0.03; 1.61) | ETD -1.00 mmol/l (95% CI -1.40; 0.60) |       |
| Rodbard et al. [15] | ETD 0.18% (95% CI -0.04; 0.41) | OR 0.50 (95% CI 0.50; 1.38) | RR 0.82 (95% CI 0.61; 1.07) | RR 0.80 (95% CI 0.50; 1.29) | ETD -1.04 kg (95% CI -1.99; -0.10) | ETD -0.31 mmol/l (95% CI -0.97; 0.34) | Lower total daily insulin dose (107 U vs 131U) after 26 weeks |

**IDegAsp OD compared to IGlar OD**

**IDegAsp OD compared to IGlar + IAsp OD**

**IDegAsp BID compared to BIAsp BID**

**Lower insulin dose of 20%**
Two studies have shown more patients achieving <7% HbA1c in 26 weeks in the once-daily IDegAsp group, with OR of 1.18 (95% CI 0.78; 1.78) [8] and 2.21 (95% CI 1.25; 3.92) [9]. Once-daily administration of IDegAsp compared to once-daily IGLar + IAsp showed no significant reduction of HbA1c levels, weight gain, and fasting glucose levels. However, the number of participants reaching normal levels of HbA1c in IDegAsp compared to IGLar + IAsp is significant with an OR of 1.07 (95% CI 0.74; 1.54). Twice a day IDegAsp administration showed no inferiority, nor superiority compared to BIAsp in terms of HbA1c reduction [10-14]. More patients achieved normal HbA1c levels with bi-daily IDegAsp in three out of four studies assessing this outcome, with OR 1.60 (95% CI 0.94; 2.72) [11], OR 1.20 (95% CI 0.59; 2.46) [12], and OR 2.22 (95% CI 1.47; 3.55) [13]. Moreover, there were three studies [11,13,14] that stated a lower risk of hypoglycemia incident in twice a day IDegAsp administration with the lowest RR of 0.46 (95% CI 0.35; 0.61) fold. In addition, five studies showed that twice a day IDegAsp administration showed more reduction in fasting glucose compared to BIAsp [10-14], with the largest margin ETD of -1.50 (95% CI -1.98; -1.01) mmol/l. Two studies reported there was a lower insulin dose of twice-daily IDegAsp up to 20% compared to BIAsp by week 26 of administration [11,13].

Based on our meta-analysis, we found a significant HbA1c reduction in administration of IDegAsp compared to IGLar once daily up to -0.12 (95% CI -0.22, -0.02) (Figure 2).

![FIGURE 2: Forest plot and funnel plot of pooled analysis on HbA1C changes](image)

IDegAsp: insulin degludec/insulin aspart; IGLar: insulin glargine; IAsp: insulin aspart; BIAsp: bi-daily insulin aspart; OD: once-daily; BID: bis in die (twice a day)

The forest plot uses effect measure of mean estimated treatment difference (ETD) [2,3,8-15]

In addition, better fasting glucose changes were seen significantly in IDegAsp with a mean difference of -0.31 (95% CI -0.49; -0.29) (Figure 3).

![FIGURE 3: Forest plot and funnel plot of pooled analysis on FPG changes](image)

IDegAsp: insulin degludec/insulin aspart; IGLar: insulin glargine; IAsp: insulin aspart; BIAsp: bi-daily insulin aspart; OD: once-daily; BID: bis in die (twice a day); FPG: fasting glucose plasma

The forest plot uses effect measure of mean estimated treatment difference (ETD) [2,3,8-15]

It was also seen when compared to BIAsp twice daily with a mean difference of -1.22 (95% CI -1.39; -1.05). However, the significance of patients reaching normal HbA1c levels in the IDegAsp group still could not be
determined (OR 1.14; 95% CI 0.99; 1.30) under homogeneously distributed data, while stating the superiority of IDegAsp in the analysis (Figure 4).

FIGURE 4: Forest plot and funnel plot of pooled analysis on proportions of participants achieving normal HbA1C

IDegAsp: insulin degludec/insulin aspart; IGlar: insulin glargine; IAsp: insulin aspart; BiAsp: bi-daily insulin aspart; OD: once-daily; BID: bis in die (twice a day)

The forest plot uses effect measure of mean estimated treatment difference (ETD) [2,3,8-15]

Safety of IDegAsp: Hypoglycemia incident and weight gain increment

In terms of safety, once-daily administration of IDegAsp resulted in lower rate of incidence of overall hypoglycemia compared to once-daily IGlar + IAsp (RR 0.90 (95% CI 0.67; 1.22)), bi-daily IAsp (RR 0.94 95% (CI 0.88; 1.01)), and bi-daily IAsp + IDeg (RR 0.89 (95% CI 0.77; 1.01)). In contrast, compared to once-daily IGlar, IDegAsp showed a higher incidence of overall hypoglycemia (RR 1.10 (95% CI 0.99; 1.22)) (Figure 5). Pooled analysis of every subgroup resulted in a better IDegAsp safety profile in overall hypoglycemia (RR 0.98 (95% CI 0.93; 1.03)). However, pooled analysis and subgroup analysis of overall hypoglycemia showed wide confidence intervals, under homogeneously distributed data. All outcomes also showed a nonsignificant difference between the two comparisons, hence it might only be stated as indicative.

FIGURE 5: Forest plot and funnel plot of pooled analysis on overall hypoglycemia incident rate

IDegAsp: insulin degludec/insulin aspart; IGlar: insulin glargine; IAsp: insulin aspart; BiAsp: bi-daily insulin aspart; OD: once-daily; BID: bis in die (twice a day)

The forest plot uses effect measure of mean estimated treatment difference (ETD) [2,3,8-15]

Subgroup analysis showed statistically significant lower risk of nocturnal hypoglycemia in IDegAsp administration compared to once-daily IGlar (RR 0.56 (95% CI 0.41; 0.76)), once-daily IAsp (RR 0.55 (95% CI 0.35; 0.87)), and bi-daily IAsp (RR 0.53 (95% CI 0.43; 0.67)) (Figure 6).
FIGURE 6: Forest plot and funnel plot of pooled analysis on nocturnal hypoglycemia incident rate

IDegAsp: insulin degludec/insulin aspart; IGlar: insulin glargine; IAsp: insulin aspart; BiAsp: bi-daily insulin aspart; OD: once-daily; BID: bis in die (twice a day)

The forest plot uses effect measure of mean estimated treatment difference (ETD) [2,3,8-15].

There were also four studies that reported a lower incidence of nocturnal hypoglycemia in IDegAsp administration twice daily with the lowest RR of 0.25 (95% CI 0.16; 0.38) fold [11-14]. According to one study, we also found a lower incidence of nocturnal hypoglycemia in the once-a-day IDegAsp group compared to the IGlar group by 75% [8]. Comparison with bi-daily IDeg+IAsp (different formulation) consisting of one study showed inferior results of IDegAsp administration to nocturnal hypoglycemia (RR 1.13 (95% CI 0.67; 1.89)), though statistically insignificant. Pooled analysis of subgroups showed a statistically significant reduction of nocturnal hypoglycemia in the administration of IDegAsp (RR 0.58 (95% CI 0.50; 0.68)).

The result of weight gain varied between subgroups as shown in Figure 7.

FIGURE 7: Forest plot and funnel plot of pooled analysis on weight gain increment

IDegAsp: insulin degludec/insulin aspart; IGlar: insulin glargine; IAsp: insulin aspart; BiAsp: bi-daily insulin aspart; OD: once-daily; BID: bis in die (twice a day)

The forest plot uses effect measure of mean estimated treatment difference (ETD) [2,3,8-15].

Administration of once-daily IDegAsp showed higher weight gain compared to once-daily IGlar (ETD 0.72 (95% CI 0.43; 0.67)) with non-homogenous data distribution, to once daily IAsp (ETD 0.43 (95% CI -0.13; 0.99)). Bi-daily administration of IDegAsp also showed higher weight gain compared to bi-daily IAsp (ETD 0.22 (95% CI -0.24; 0.29)). However, administration of IDegAsp co-formulation in one study could decrease weight gain incidence compared to its separate formulation (ETD -1.04 (95% CI -1.98; -0.10)). Pooled analysis showed a higher incidence of weight gain in IDegAsp administration; however, the data is deemed inconclusive due to wide confidence intervals, the variance between subgroups, and high heterogeneity.

Discussion

IDegAsp is the first soluble co-formulation insulin and comprises two insulin analogues that cover both
Once-daily IDegAsp administration gave a better HbA1c reduction compared to once-daily IGLar, which could not be explained clearly by twice-daily IDegAsp administration [9-14]. It was also determined that once-daily IDegAsp compared to once-daily IGLar was the only subgroup with a significant difference in our meta-analysis (mean difference -0.12; 95% CI -0.22; -0.02). It was similar to one study that there was HbA1c elevation in the first three months of once-daily basal insulin administration (8.70%±1.00%; p<0.05) and HbA1c reduction in the first three months of changing into once-daily IDegAsp (8.28%±1.10%; p<0.05) with significant effect up to six months of the administration [18]. There was a study that stated that IDegAsp administration was not linked with the difference in HbA1c in insulin-naive patients; however, the same study stated there was a reduction of FPG by 1.0 mmol/l (p<0.05), which could not be determined in all studies included [8]. This mechanism could be explained by the fact that IDegAsp consists of IDeg di-hexamers and IAsp hexamers. IDeg di-hexamers create a pool of soluble multi-hexamers that continuously form into monomers, thus slowly dissociating. Meanwhile, IAsp hexamers dissociate swiftly to monomers. IDeg has a half-life of 25.3 hours with a duration of action of up to 42 hours, while IAsp acts rapidly in 10-15 minutes of onset and reaches peak action in 90 minutes [8,19]. Due to its sustainability and bioavailability, once-daily IDegAsp was proven enough to lower HbA1c levels. These traits were also proven on lowering fasting glucose levels, which was proven further by our meta-analysis (mean difference -0.31; 95% CI -0.49; -0.29). Therefore, it is currently known that IDegAsp is considered superior to certain other insulin in a matter of both short-term and long-term actions in lowering blood glucose levels and HbA1c.

In the terms of safety, we have found that IDegAsp’s long-acting trait did not improve the risk of nocturnal hypoglycemia as we saw that there is a reduction of nocturnal hypoglycemia in one study [8]; with all studies showing statistically insignificant results in the superiority of IDegAsp. Nocturnal hypoglycemia incidence reduction was achieved in both once-daily and twice-daily administration of IDegAsp in comparison to IAsp and IGLar; although a separate formulation of IDeg/IAsp showed better results compared to the IDegAsp co-formulation [8,11-14]. This was contributed by the stability of IDeg di-hexamers so that impact of rapid and slow-acting insulin was clearly separated. It is known by the same study that IDegAsp metabolism and excretion were not impaired by renal or liver impairment at any level [20]. Therefore, there was a lower risk of IDegAsp-related toxicity. However, there is a higher risk of hypoglycemia in once-daily administration of IDegAsp according to two studies [3,8]. It was stated that hypoglycemic events peaked in the evening, between 20:00 and 24:00 with the majority of subjects taking a once-daily IDegAsp post the evening meal. In contrast, once-daily IGLar administration post evening meals showed hypoglycemic effects between 04:00 and 08:00 [3]. These phenomena were linked with the onset activity of IDegAsp and IGLar, which differed. IDegAsp showed a peak glucose-lowering effect four hours after administration and slowed up to 24 hours after administration [21]. Therefore, to achieve a reduction of HbA1c using once-daily IGLar without risking hypoglycemia, it is recommended to give an initial dose at the largest mealtime with tapering if needed. It has been proven that hypoglycemia incidence was significantly reduced by IDegAsp administration on the largest meal of the day. It also gave better FPG reduction after 26 weeks [8].

Hypoglycemia also could be reduced by using a stepwise titration scheme [22]. As an alternative, three studies suggested that twice a day IDegAsp administration could lower the risk of hypoglycemia based on a lower dose [11,13,14], which could be reduced to 80% of the basal insulin dose according to two studies [13,14]. Twice a day IDegAsp administration also showed a greater effect in FPG reduction in once-daily administration, according to five studies [10-14]. However, there was a study stating the inconvenience of twice daily insulin contributed to 6% of non-adherence to insulin administration protocol [23]. Therefore, twice-daily administration of IDegAsp should be re-evaluated even though there is a lower risk of hypoglycemia compared to once-daily administration.

The relation between IDegAsp administration, both once daily and twice daily, and weight gain could not be determined due to its wide CI and high heterogeneity [8,11,15]. This finding correlated with two other studies [9,14], which found weight gain in both arms of IDegAsp and basal insulin. One study mentioned before stated weight gain as an adverse effect of IDegAsp administration with a high dose on patients with a higher risk of hypoglycemia [8]. Therefore, there was a relation between dosing and weight gain in IDegAsp.
administration, both once daily and twice daily, with other types of insulin showing similar weight gain effects.

This is a systematic review that positioned various frequencies of IDegAsp administration among other established insulin administration in terms of efficacy and safety. However, this study involved some phase III randomized controlled trials (RCTs), considered by some as not eligible for quantitative review. Therefore, high-quality RCTs on the efficacy of IDegAsp on certain populations should be done to provide more data for meta-analysis in order to produce pooled variables of IDegAsp’s efficacy and safety.

Conclusions
IDegAsp once-daily administration was proven more beneficial in terms of HbA1c reduction and lowering nocturnal hypoglycemia incidence, but not hypoglycemia incidence and weight gain. On the other hand, IDegAsp twice-daily administration was not yet proven in HbA1c reduction and reduced weight gain but proven in lowering hypoglycemia incidence and nocturnal hypoglycemia incidence. Therefore, considering compliance and convenience, we suggest once-daily administration of IDegAsp with a stepwise titration scheme on the largest meal of the day to achieve benefit while minimizing risk. In addition, we would like to suggest more RCTs performed in order to provide more data for quantitative analysis of efficacy and safety.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
The authors would like to express their gratitude to Dr. Wismandari Wisnu for her guidance on the writing of this topic.

References
1. Global Report on Diabetes. World Health Organization, Geneva, Switzerland; 2016. https://apps.who.int/iris/rest/bitstreams/909858/retrieve.
2. Philis-Tsimikas A, Astamirova K, Gupta Y, et al.: Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019, 147:157-65. 10.1016/j.diabres.2018.10.024
3. Kumar S, Jang HC, Demirag NG, Skjoth TV, Endahl L, Bode B: Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study. Diabet Med. 2017, 34:180-8. 10.1111/dme.13125
4. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136/bmj.n71
5. Critical Appraisal of Prognostic Studies. Centre for Evidence-Based Medicine, University of Oxford, Oxford, United Kingdom; 2022. http://www.cebm.net/wp-content/uploads/2014/04/cebm-prognosis-worksheet.pdf
6. Higgins JP, Altman DG, Gøtzsche PC, et al.: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136/bmj.d5928
7. OCEBM Levels of Evidence. (2022). Accessed: May 20, 2022: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocemb-levels-of-evidence.
8. Kumar A, Awata T, Bain SC, et al.: Clinical use of the co-formulation of insulin degludec and insulin aspart. Int J Clin Pract. 2016, 70:657-67. 10.1111/iopc.12821
9. Onishi Y, Ono T, Rabol R, Endahl L, Nakamura S: Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab. 2015, 15:826-32. 10.1111/dom.12097
10. Kaneko S, Chow F, Choi DS, et al.: Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomized, treat-to-target trial. Diabetes Res Clin Pract. 2015, 107:139-47. 10.1016/j.diabres.2014.09.026
11. Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, Niskanen LK: Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014, 37:2084-90. 10.2337/dc13-15298
12. Taneda S, Hylestved-Winge J, Gall MA, Kaneko S, Hirao K: Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: subgroup analysis of a Pan-Asian, treat-to-target phase 3 trial. J Diabetes. 2017, 9:243-7. 10.1111/1753-4407.12407
13. Yang W, Ma J, Hong T, et al.: Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin
aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial. Diabetes Obes Metab. 2019, 21:1652-60. 10.1111/dom.13705

14. Franek E, Haluzík M, Caneeviči Šaržič S, Sargin M, Macura S, Zacho J, Christiansen JS: Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with type 2 diabetes. Diabet Med. 2016, 33:497-505. 10.1111/dme.12982

15. Rodbard HW, Cariou B, Pieber TR, Endahl LA, Zacho J, Cooper IG: Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IASp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. Diabetes Obes Metab. 2016, 18:274-80. 10.1111/dob.12609

16. Kalra S: Insulin degludec aspart: the first co-formulation of insulin analogues. Diabetes Ther. 2014, 5:65-72. 10.1007/s13300-014-0067-x

17. John M, Gopinath D, Oommen T: Co-formulations as the first injectable in type 2 diabetes: a review of efficacy, safety, and implications in clinical practice. Dubai Diabetes Endocrinol J. 2020, 26:159-51. 10.1159/000509045

18. Jang HN, Yang YS, Lee SO, Oh TJ, Koo BK, Jung HS: Favorable glycemic control with once-daily insulin degludec/insulin aspart after changing from basal insulin in adults with type 2 diabetes. Endocrinol Metab (Seoul). 2019, 34:382-9. 10.3803/EnM.2019.34.4.382

19. Kalra S, Latif ZA, Comlekci A, Galvez GG, Malik R, Pathan MF, Kumar A: Pragmatic use of insulin degludec/insulin aspart co-formulation: a multinational consensus statement. Indian J Endocrinol Metab. 2016, 20:542-5. 10.4103/2230-8210.182980

20. Unnikrishnan AG, Singh AK, Modi KD, Saboo B, Garcha SC, Rao PV: Review of clinical profile of IDegAsp. J Assoc Physicians India. 2015, 63:15-20.

21. Haata H, Fita EG, Heine T: A review of insulin degludec/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use. Clin Pharmacokinet. 2017, 56:339-54. 10.1007/s40262-016-0455-7

22. Gerety G, Bebakar WM, Chaykin L, Ozkaya M, Macura S, Henslev ML, Behnke T: Treatment intensification with insulin degludec/insulin aspart twice daily: randomized study to compare simple and step-wise titration algorithms. Endocr Pract. 2016, 22:546-54. 10.4158/EP15893.OR

23. Doggrell SA, Chan V: Adherence to insulin treatment in diabetes: can it be improved? J Diabetes. 2015, 7:315-21. 10.1111/1753-0407.12212